共 152 条
[41]
Shalaev E(2015)Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle Genet Med 17 405-24
[42]
Karami TK(2019)Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology JAMA Ophthalmol 137 1-undefined
[43]
Cunningham J(2020)Utility of in vitro mutagenesis of RPE65 protein for verification of mutational pathogenicity before gene therapy Expert Opin Orphan Drugs 8 67-undefined
[44]
Slater NKH(2019)Monitoring progression of retinitis pigmentosa: current recommendations and recent advances J Am Assoc Pediatr Ophthalmol Strabismus 23 e7-undefined
[45]
Rivers HM(2020)How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA/inherited retinal disease Pharmacoeconomics 38 1309-undefined
[46]
Acland GM(2020)Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations: an evidence review group perspective of a NICE highly specialised technology appraisal Expert Opin Biol Ther 20 565-undefined
[47]
Aguirre GD(2019)Voretigene neparvovec-rzyl for treatment of J AAPOS 23 226-undefined
[48]
Bennett J(2020)-mediated inherited retinal diseases: a model for ocular gene therapy development Ophthalmologe 117 16-undefined
[49]
Acland GM(undefined)Survey of practice patterns for the management of ophthalmic genetic disorders among AAPOS members: report by the AAPOS Genetic Eye Disease Task Force undefined undefined undefined-undefined
[50]
Aguirre GD(undefined)Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna) in ophthalmology. English version: January 2019 undefined undefined undefined-undefined